Analyst firms · Evercore ISI · RNA
Evercore ISI RNA price target and rating history
Atrium Therapeutics Inc. (RNA) · Health Care
Evercore ISI rates Atrium Therapeutics Inc. (RNA) Outperform with a $20 price target, as of its latest action on May 22, 2023. It has published 3 rating actions on RNA since September 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a RNA price target in the last 12 months, the median target is $25.
- Current rating
- Outperform
- Price target
- $20
- Median target, all firms
- $25
- Actions on RNA
- 3
Evercore ISI price target on RNA
Every Evercore ISI rating on RNA
- May 22, 2023
- Mar 31, 2023
- Sep 7, 2021
How other firms rate RNA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $15 | Oct 22, 2026 |
| H.C. Wainwright | Buy | $25 | Aug 6, 2026 |
| Cantor Fitzgerald | Overweight | $25 | Jun 18, 2026 |
| Leerink Partners | Outperform | $25 | May 15, 2026 |
| Wells Fargo | Overweight | $25 | Mar 11, 2026 |
Questions about Evercore ISI and RNA
- What is Evercore ISI's price target for RNA?
- Evercore ISI's latest stated price target for Atrium Therapeutics Inc. (RNA) is $20, from its action on May 22, 2023.
- What is Evercore ISI's rating on RNA?
- Evercore ISI rates RNA Outperform, a bullish rating, as of May 22, 2023.
- When did Evercore ISI last change its view on RNA?
- On May 22, 2023, Evercore ISI upgrades to Outperform from In-line, price target $20.
- How does Evercore ISI's RNA target compare with other analysts?
- Across 5 firms with a RNA price target in the last 12 months, the median target is $25.
All Evercore ISI ratingsRNA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.